Isoniazid-induced hepatotoxicity in children with latent tuberculosis infection.

Autor: Devrim, İlker; Devrim, Fatma; Bayram, Nuri; Aktürk, Hüseyin; Aksay, Ahu; Can, Demet; Apa, Hurşit

Publication year: 2021

Minerva pediatrics

issn:2724-5780

doi: 10.23736/S2724-5276.17.04338-9

Abstract:

BACKGROUND: We aimed to determine overall incidence of severe and mild isoniazid (INH) hepatotoxicity and outcome of hepatotoxicity in children who were receiving INH for latent tuberculosis. METHODS: Patients who had received isoniazid for treatment of latent tuberculosis were included in the study. Hepatotoxicity was classified according to the World Health Organization Toxicity Classification Standards. RESULTS: Among 1038 patients, overall hepatotoxicity was observed in 22 patients (2.2%), while 5 patients (0.48%) had moderate-severe hepatotoxicity; while other 17 patients had grade I-II hepatotoxicity (1.63%). Age and gender did not appear to be risk factors for hepatotoxicity. The median time for therapy rechallenge in patients with grade III-IV hepatotoxicity was 21 days (ranging from 14 to 25 days). CONCLUSIONS: Isoniazid hepatotoxicity is lower and generally reversible after cessation of INH in children. The grade of hepatotoxicity affects the duration for recovery of hepatotoxicity and restarting of INH therapy.

Language: eng

Rights:

Pmid: 26377643

Tags: Humans; Female; Male; Incidence; Child; Infant, Newborn; Adolescent; Child, Preschool; Infant; Antitubercular Agents/*adverse effects; Chemical and Drug Induced Liver Injury/*epidemiology/pathology; Isoniazid/*adverse effects; Latent Tuberculosis/*drug therapy

Link: https://pubmed.ncbi.nlm.nih.gov/26377643/